Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Menstruation Disturbances

ClinicalTrials.gov lists 837 trials for Menstruation Disturbances or a narrower condition beneath it. Bayer has the most among industry and government lead sponsors, with 31.

MeSH D008599 Pathological Conditions, Signs and Symptoms C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 24 Phase 1/2 Phase 1/2 11 Phase 2 Phase 2 56 Phase 2/3 Phase 2/3 7 Phase 3 Phase 3 107 Phase 4 Phase 4 63 Not applicable Not applicable 403 Observational Observational 166 Phase 1 Phase 1 24 Phase 1/2 Phase 1/2 11 Phase 2 Phase 2 56 Phase 2/3 Phase 2/3 7 Phase 3 Phase 3 107 Phase 4 Phase 4 63 Not applicable Not applicable 403 Observational Observational 166

Trials per phase (log scale)

103 of the 837 trials are tagged with Menstruation Disturbances itself; the rest are tagged with a narrower condition beneath it.

Get the Menstruation Disturbances report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Menstruation Disturbances trials start? (33)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 86

1991: 1 trials (Observational 1) 1992: 2 trials (Observational 1, Phase 1 1) 1994: 1 trials (Phase 3 1) 1997: 2 trials (Observational 1, Phase 3 1) 1998: 2 trials (Phase 4 1, Phase 2 1) 1999: 1 trials (Not applicable 1) 2000: 7 trials (Observational 1, Not applicable 3, Phase 4 1, Phase 2 2) 2001: 7 trials (Not applicable 4, Phase 2 2, Phase 1/2 1) 2002: 9 trials (Phase 4 1, Phase 3 5, Phase 2 3) 2003: 8 trials (Not applicable 3, Phase 4 1, Phase 3 3, Phase 2/3 1) 2004: 10 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 4, Phase 2 1, Phase 1 2) 2005: 18 trials (Observational 2, Not applicable 1, Phase 4 2, Phase 3 9, Phase 2 4) 2006: 16 trials (Observational 3, Not applicable 4, Phase 4 2, Phase 3 6, Phase 2 1) 2007: 18 trials (Not applicable 3, Phase 4 2, Phase 3 5, Phase 2/3 2, Phase 2 3, Phase 1/2 3) 2008: 18 trials (Observational 5, Not applicable 5, Phase 4 3, Phase 3 2, Phase 2 2, Phase 1 1) 2009: 14 trials (Observational 3, Not applicable 1, Phase 4 3, Phase 3 3, Phase 2 3, Phase 1 1) 2010: 14 trials (Observational 1, Not applicable 3, Phase 4 2, Phase 3 3, Phase 2 2, Phase 1/2 1, Phase 1 2) 2011: 28 trials (Observational 6, Not applicable 10, Phase 4 4, Phase 3 5, Phase 2 2, Phase 1 1) 2012: 30 trials (Observational 11, Not applicable 10, Phase 3 8, Phase 2 1) 2013: 31 trials (Observational 5, Not applicable 12, Phase 4 5, Phase 3 3, Phase 2 4, Phase 1/2 1, Phase 1 1) 2014: 26 trials (Observational 6, Not applicable 7, Phase 4 4, Phase 3 4, Phase 2/3 1, Phase 2 2, Phase 1 2) 2015: 27 trials (Observational 1, Not applicable 10, Phase 4 3, Phase 3 8, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 1) 2016: 28 trials (Observational 5, Not applicable 8, Phase 4 3, Phase 3 6, Phase 2 3, Phase 1/2 1, Phase 1 2) 2017: 37 trials (Observational 8, Not applicable 10, Phase 4 3, Phase 3 13, Phase 2 2, Phase 1 1) 2018: 34 trials (Observational 6, Not applicable 16, Phase 4 4, Phase 3 5, Phase 2 1, Phase 1/2 1, Phase 1 1) 2019: 30 trials (Observational 4, Not applicable 12, Phase 4 4, Phase 3 5, Phase 2/3 1, Phase 2 3, Phase 1 1) 2020: 28 trials (Observational 11, Not applicable 10, Phase 4 2, Phase 3 3, Phase 2 1, Phase 1 1) 2021: 34 trials (Observational 11, Not applicable 20, Phase 4 3) 2022: 55 trials (Observational 11, Not applicable 39, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 2) 2023: 69 trials (Observational 16, Not applicable 47, Phase 4 1, Phase 3 1, Phase 2 1, Phase 1/2 1, Phase 1 2) 2024: 77 trials (Observational 16, Not applicable 57, Phase 4 2, Phase 3 1, Phase 2 1) 2025: 86 trials (Observational 13, Not applicable 65, Phase 4 3, Phase 2 3, Phase 1/2 1, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 58
2025 86
2024 77
2023 69
2022 55
2021 34
2020 28
2019 30
2018 34
2017 37

Showing 10 of 33 earlier years.

Start your 14-day trial Email me all 33 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 73 trials starting in 2026 and about 74 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 32 months from start to primary completion across 44 trials still running at the 2026-10-09 snapshot; registered median of 14 months across 519 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Menstruation Disturbances trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 24
Phase 1/2 11
Phase 2 56
Phase 2/3 7
Phase 3 107
Phase 4 63
Not applicable 403
Observational 166

How many Menstruation Disturbances trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 45
Recruiting 78
Enrolling by invitation 6
Active, not recruiting 19
Completed 494

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Menstruation Disturbances trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Bayer 31
AbbVie 15
Abbott 15
Myovant Sciences GmbH 8
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 7

Showing 5 of 7 sponsors.

Start your 14-day trial Email me all 7 sponsors as a PDF

Which drugs are being tested for Menstruation Disturbances? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Elagolix 15
Asoprisnil 10
Relugolix 8
Levonorgestrel 7

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
acid tranexamic 16
Estradiol /norethindrone acetate (E2/NETA) 14
Aerobic exercise 9
Ibuprofen 2% 7
1: Naproxen 7

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Menstruation Disturbances trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Hospitalizations for low weight and/or bradycardia 28 1
ANAEMIA 16 5
PELVIC PAIN 13 7
ABDOMINAL PAIN 10 3
ABORTION INDUCED 10 5

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Menstruation Disturbances? (158)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Menstrual disorder is associated with blood type in PCOS patients: evidence from a cross-sectional survey. BMC endocrine disorders 2025 Yes
The menstrual distress questionnaire (MEDI-Q): reliability and validity of the English version. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2023 Yes
Menstrual Distress Questionnaire (MEDI-Q): a new tool to assess menstruation-related distress. Reproductive biomedicine online 2021 Yes
Menstrual Dysfunction in Women With Schizophrenia During Risperidone Maintenance Treatment. Journal of clinical psychopharmacology 2021 Yes
Randomised controlled trial of the effects of increased energy intake on menstrual recovery in exercising women with menstrual disturbances: the 'REFUEL' study. Human reproduction (Oxford, England) 2021 Yes

Showing 5 of 158 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (5)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages